INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the synovial tissue that leads to progressive joint destruction. Among the cells located in the inflamed joint, synovial fibroblasts are important players driving inflammation and bone erosion.
They are recognized as a source of cytokines such as IL-6 or RANKL which activate immune response [1 ] and osteoclastogenesis. There is evidence that the Colony Stimulating Factors (CSFs) play a major role in inflammation and bone destruction in RA. Macrophage-CSF (M-CSF) is the primary regulator of the biology of mononuclear phagocytes and is also essential [2 ] for osteoclastogenesis.
In the synovial tissue of RA patients, it is expressed by the macrophages but also by the synovial fibroblasts and [3 ] is up-regulated by inflammatory cytokines like TNF-. , Furthermore, M-CSF knockout mice are protected against collagen-induced α [2 4 ] arthritis, and M-CSF administration exacerbates inflammation and joint destruction. ,
In this context, therapeutic targeting of M-CSF [2 5 ] is currently being developed. [2 ] IL-34 is a newly discovered cytokine which plays a role in macrophage differentiation and proliferation.
IL-34 is expressed in [6 ] various tissues and it is most abundant in the spleen. This cytokine shares numerous common features with M-CSF, especially its receptor (MCSF-R) explaining partly their functional overlap. However, their interaction with MCSF-R, the signalling pathway activated and their expression patterns differ during the embryonic development underlining their probable specific biological function. Recently, we have [7 ] shown that IL-34 could be substituted for M-CSF to promote osteoclastogenesis . Its role in inflammation is also likely as IL-34 in vitro [8 ] increase IL-6 and chemokine level in human whole blood.
Although numerous studies have underlined the role of M-CSF in arthitis, no [9 ] data are currently available on the expression of IL-34 in RA.
In this study, we hypothesized that IL-34 could be expressed by the synovial fibroblasts of RA patients and this expression could be modulated by TNF and IL-1 .
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METHODS

Synovial fluid and biopsies
Synovial biopsies were obtained surgically at the time of an arthroplasty and were summarized in . All patients enrolled have Table S1 given their formal consent. The study was approved by the local ethics committee and by the French Research Ministry (N 2008-402 ). The°m ean ( / SD) duration of the RA was 11 / 5 years and the mean synovitis score was 4.4 / 1.9 (range 2 8). The mean score of synovial
hyperplasia, stroma activation and inflammatory infiltrates was 1.3 / 1.2, 1.5 / 0.6 and 1.6 / 0.5 respectively ( ). IL-34 Table S1 expression was detected by immunohistochemistry performed as previously described. The histopathological severity of synovitis was [8 ] graded as described by Krenn et al. IL-34 levels were measured in synovial fluids by ELISA assay (antibodies-online-GmbH, USA) [11 ] according the manufacturer s recommendations.
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Cell cultures
Synovial fibroblasts, obtained from the synovial tissue of RA patients, human fibroblasts (WI-26) and murine wild type, -jnk1 / − − jnk2 − and fibroblast cell lines were cultured as previously described.
Reverse Transcription-PCR analysis
Total RNA was extracted using NucleoSpin RNAII kit (Macherey-Nagel, France) and one microgram of total RNA was used for first strand cDNA synthesis using Thermoscript kit (Invitrogen, France). Real-time PCR was performed using SYBRGreen Supermix [8 ] (Biorad, France) and primers described in . Table S2
Statistical analysis
Mann-Whitney test was use to look for an association between Il-34 expression and the histological characteristics. Correlation between level of IL-34 and leukocytes count in the synovial fluid was measured using the nonparametric Spearman rank order test. Student t-test was used to assess the change in gene expression. p<0.05 was considered as statistically significant.
RESULTS
IL-34 is expressed in the synovial tissue of RA and OA patients
We first assessed the expression of in the synovial tissue in synovial biopsy from patients suffering from rheumatoid arthritis (n IL-34 = 20), osteoarthritis (n 3) or other inflammatory arthritis (n 4) ( ). According to the grading system of all the biopsies, 11 had slight = = Table S1 synovitis, 9 had moderate synovitis, and 7 had strong synovitis. IL-34 was detected in 24 of the 27 biopsies with 3 samples from RA patients being negative. In the synovial tissue, IL-34 was expressed in the synovial lining layer by the synoviocytes and macrophages ( Fig.   ) as confirmed by the double immmunostaining for IL-34 and CD68 ( ) and in the sub-lining layer by endothelial cells and 1A, B Fig. S1 fibroblasts ( ). In RA patients, a significant association was found between IL-34 expression in the synovial lining layer and the plateau from 25ng/mL and a maximum of induction after 6 hours with 10ng/mL ( ). The time course study using 10ng/mL TNF- Fig. 2A α shows that this effect remained stable until 24 hours (data not shown). Similarly, Il-1 also increased dose-dependently IL-34 mRNA β expression with a peak reached at 6h then decreased quickly thereafter ( ). Confocal microscopy ( ) and flow cytometry (  Fig. 2B  Fig. 2C ) analyses confirmed that TNF-and Il-1 upregulated the expression by synovial fibroblasts of IL-34 at the protein level Fig. S2 α β compared to the untreated cells peaking at 6 and 10h respectively, and remaining at levels significantly higher than their basal expression state up to 24h and 48h. To understand the mechanisms by which TNF-and IL-1 are able to stimulate IL-34 mRNA levels, the role played by the JNK and NF-B SP600125) the effect of 10ng/mL TNF-( ) after treatment of the cells with 10ng/ml of TNF-( ) or IL-1 (data not α Fig. 3D α Fig. 3C β shown). Confocal microscopy analyses confirmed the effects of signaling pathway inhibitors at the protein level ( ). Fig. S3 
DISCUSSION
Pro-inflammatory cytokines, promoting inflammation and osteoclastogenesis in the arthritic joint, are fundamental to RA pathophysiology.
In this study we demonstrated that a newly discovered cytokine, IL-34, is expressed by the synovial fibroblasts and We have shown that TNF-and IL-1 are able to enhance IL-34 expression in RA synovial fibroblasts. These results were Synovial fibroblasts from RA patients (n 3) were stimulated with increased dose of TNF-(1 to 50 ng/mL) for 6h hours or with TNF = (A) α -α 10 ng/mL for 2h, 6h, 10h and 24h and increased dose of IL-1 (1 to 25 ng/mL) for 6 hours or with IL-1 10 ng/mL for 2h, 6h, 10h and (B) β β 24h. After incubations, IL-34 mRNA levels were determined by real time RT-PCR, normalized to GAPDH Synovial fibroblasts cultured (C) on labtek chamber slides (Millipore, France) were treated or not with TNF (10 ng/mL) or IL-1 (10 ng/mL) for 24h. IL-34 expression -α β (green), actin filaments detected by alexa fluor 546-conjugated phalloidin (red), and nuclei stained by DAPI (blue) were observed by confocal microscopy. A representative experiment was shown.
